Matricelf Ltd
TASE:MTLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Matricelf Ltd
Cash Equivalents
Matricelf Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Cash Equivalents
₪86k
|
CAGR 3-Years
-84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash Equivalents
$75.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
31%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash Equivalents
$314k
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-27%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash Equivalents
$110.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash Equivalents
$7.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash Equivalents
$4.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Cash Equivalents?
Cash Equivalents
86k
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Cash Equivalents amounts to 86k ILS.
What is Matricelf Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
-84%
Over the last year, the Cash Equivalents growth was -97%. The average annual Cash Equivalents growth rates for Matricelf Ltd have been -84% over the past three years .
